Home Biosimilar Antibodies Apoptosis Others Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)
For research use only. Not for use in humans.

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Synonyms: AMG 655,TRAIL-R2 mAb

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD.

Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Quality Control

Batch: A233101 Purity: 99% Protein concentration: 6.44mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD.

Product Details

CAS No.  896731-82-1
Molecular Weight 144.96 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.